EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 中國同輻股份有限公司 | | 股份代號 | 01763 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年9月12日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | 更新股東批准日期、除淨日、為符合獲取股息分派而遞交股份過戶文件之最後時限、暫 | | 停辦理股份過戶登記手續之日期、記錄日期及股息派發日 | | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.0807 RMB | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 茲提述中國同輻股份有限公司（「本公司」）日期為2025年8月28日的通函（「通 函」）以及日期為2025年8月28日的本公司2025年第二次臨時股東會通告（「原有通 告」），藉以考慮及通過建議聘任境內2025年度審計機構及建議中期股息。除文義 另有所指外，本公告所用詞彙與通函所界定者具有相同涵義。 （股份代號：1763） 延期召開臨時股東會 及 變更中期股息暫停辦理股份過戶登記期間、記錄日期及付息日期 延期召開臨時股東會 臨時股東會原定於2025年9月17日（星期三）上午十時正舉行，藉以考慮及酌情通 過原有通告所載決議案。本公司謹此宣佈，因統籌會議工作安排需要，臨時股東 會將延期至2025年10月17日（星期五）上午十時正舉行。延期臨時股東會之舉行 地點保持不變，為中國北京市海淀區廠窪中街66號4樓403室。 中國同輻股份有限公 ...

Group 1 - The core viewpoint of the article highlights the strategic cooperation between China National Nuclear Corporation (CNNC) and China Nuclear Environmental Protection (CNEP) in various nuclear technology and environmental applications [1] - Both parties agreed to collaborate closely on the application platform for low-energy electron accelerators, the quality improvement and reuse of waste sources, and the establishment of radiation safety standardization systems for medical centers [1] - The meeting aimed to accelerate project research in these key areas of nuclear technology and environmental protection [1]

Core Viewpoint - China Tongru (01763) has successfully developed a new type of Suπone13C breath analyzer, achieving independent breakthroughs in Helicobacter pylori breath detection technology, providing a more reliable, efficient, and convenient solution for diagnosis [1] Group 1: Product Development - The new Suπone13C breath analyzer has obtained a Class II medical device registration certificate [1] - The analyzer offers stable detection results and high detection efficiency, reducing the sample testing time from a minimum of 2 minutes in the industry to just 30 seconds [1] Group 2: Market Impact - The higher detection accuracy of the new device allows for broader application in large-scale screening scenarios for Helicobacter pylori [1] - The product enhances the utilization efficiency of medical resources, contributing to the establishment of an early screening and diagnosis system for gastric cancer in China [1]

Core Viewpoint - China Tongru (01763) has successfully developed a new type of Su π one 13C breath analyzer, achieving a breakthrough in the detection technology for Helicobacter pylori, providing a more reliable, efficient, and convenient solution for diagnosis [1] Summary by Relevant Categories Product Development - The new Su π one 13C breath analyzer has obtained a Class II medical device registration certificate, marking a significant advancement in the field [1] - The analyzer offers stable detection results and high efficiency, reducing the sample detection time from a minimum of 2 minutes to just 30 seconds, thereby improving user experience [1] Market Impact - With higher detection accuracy, the device can be adapted for a wider range of large-scale Helicobacter pylori screening scenarios, enhancing the utilization of medical resources [1] - This innovation contributes crucial technical support for the establishment of an early screening and diagnosis system for gastric cancer in China [1]

Core Viewpoint - China Tongru (01763.HK) has successfully developed a new type of breath analyzer, Su π oneC, which has obtained the Class II medical device registration certificate, marking a significant breakthrough in the detection technology for Helicobacter pylori [1] Company Summary - The new Su π oneC breath analyzer provides a more reliable, efficient, and convenient solution for Helicobacter pylori diagnosis [1] - The detection results of the Su π oneC are stable and efficient, reducing the sample testing time from a minimum of 2 minutes in the industry to just 30 seconds, significantly improving the user experience [1] - The device offers higher detection accuracy and is suitable for a wider range of large-scale Helicobacter pylori screening scenarios, enhancing the utilization of medical resources [1] Industry Summary - The development of the Su π oneC breath analyzer contributes critical technological support for establishing an early screening and diagnosis prevention system for gastric cancer in China [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 新型Su π one 13C呼氣分析儀檢測結果穩定，檢測效率高，一組樣本的檢測時間從 行業最少2分鐘縮短至30秒，有效改善應用體驗；憑藉「更高的檢測精度」，可適 配更廣泛的幽門螺桿菌規模化篩查場景，提升醫療資源利用效率，為我國構建胃 癌早篩早診防控體系增添關鍵技術支撐。 （股份代號：1763） 自願性公告 中國同輻新型碳-13呼氣分析儀獲批上市 本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 本公司董事會欣然宣布，近日，由中國同輻獨立自主研製的新型Su π one 13C呼氣 分析儀順利取得第二類醫療器械註冊證，實現幽門螺桿菌呼氣檢測技術的自主突 破，為幽門螺桿菌診斷提供更可靠、更高效、更便捷的解決方案。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國同輻股份有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01763 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 79,968,800 | RMB | | | 1 RMB | | 79,968,800 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 79,968,800 | RMB | | | 1 RMB | | 79,968,800 | | 2. 股份分類 | ...

Core Insights - The company reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year growth of 1.69% [2] - Shareholders' profit attributable to the company was 172 million RMB, showing an increase of 11.33% year-on-year [2] - The basic earnings per share were 0.54 RMB [2] Business Focus - The company is concentrating on two main industries: nuclear medical health and irradiation applications [2] - It provides comprehensive solutions in nuclear medicine and radiotherapy, forming a "6+N" industrial layout centered around isotopes, nuclear pharmaceuticals, nuclear medical equipment, and irradiation applications [2] - The business scope includes research, manufacturing, and sales of isotopes, radioactive drugs, and radiation sources, as well as irradiation sterilization, material modification, and EPC services for irradiation devices [2]

Core Viewpoint - China Dongfang (01763.HK) reported a revenue of RMB 2.858 billion for the six months ending June 30, 2025, representing a year-on-year increase of 2% [1] Financial Performance - Gross profit amounted to RMB 1.460 billion, showing a slight decrease of 0.3% year-on-year [1] - Profit attributable to equity shareholders was RMB 172 million, reflecting an increase of 11.3% year-on-year [1] - Basic earnings per share were RMB 0.54 [1] Margin Analysis - The gross margin decreased from 52.1% to 51.1% [1] - The decline in gross profit and gross margin was primarily due to a reduction in revenue from nuclear medicine, while other business segments with higher revenue growth had lower gross margins, which negatively impacted the overall gross margin [1]